Novel oral polio vaccine type 2 (nOPV2) has been genetically engineered to reduce the reversion events that can occur with Sabin oral polio vaccine (OPV) and result in loss of attenuation.1 As population immunity fell following the global withdrawal of...
A mass vaccination campaign with killed oral cholera vaccine (kOCV; Euvichol-Plus, EuBiologics, Seoul, South Korea) was conducted in an urban population vulnerable to cholera on the shores of Lake Tanganyika in the Democratic Republic of the Congo, fol...
Oral switch antimicrobial therapy was non-inferior to intravenous standard therapy in participants with low-risk S aureus bloodstream infection. However, it is necessary to carefully assess patients for signs and symptoms of complicated S aureus bloods...
In the October issue of The Lancet Infectious Diseases, the editorial titled Can We Control Dengue?1 takes into consideration only two aspects of dengue control: prevention by vaccination and vector control strategies. However, a very important aspect ...
As the costs and complexity of health-care delivery mount globally, there continues to be substantial interest in the use of oral antibiotic therapy for serious infections. In The Lancet Infectious Diseases, Achim Kaasch and colleagues1 evaluated the e...
I read with interest the Correspondence by Mathieu Nacher and colleagues1 in which the authors described subjecting ChatGPT3.5 to various vignettes that were reconstituted from confirmed cases of histoplasmosis in their cohort of people with HIV or HIV...
The under-representation of women in infectious diseases and clinical microbiology has been well documented.1,2 Besides publishing, active participation in scientific conferences is a crucial part of career development.3 Conferences are a focal point f...
In a campaign in west Africa, nOPV2 was well tolerated and safe. High rates of seroconversion and evidence of mucosal immunity support the licensure and WHO prequalification of this vaccine.
The Asia-Pacific region is highly vulnerable to the effect of climate change and outbreaks of climate-sensitive infectious diseases, including arthropod-borne viruses (arboviruses) such as dengue, chikungunya, and Zika virus. Addressing the region's vu...
Large-scale administration of the oral polio vaccine (OPV) has been a key pillar of polio eradication efforts. However, when used in under-immunised communities, OPV can circulate for an extended period, reverting the attenuating mutations and acquirin...
In The Lancet Infectious Diseases, Viviane Sprecher and colleagues1 reported a non-inferiority clinical trial to investigate the efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis. This trial provides invaluabl...
Current estimates of fungal disease incidence and mortality are imprecise. Population at risk denominators were used to estimate annual incidence for 2019–21. Extensive literature searches from 2010 to 2023 were combined with over 85 papers on individu...
Current estimates of fungal disease incidence and mortality are imprecise. Population at risk denominators were used to estimate annual incidence for 2019–21. Extensive literature searches from 2010 to 2023 were combined with over 85 papers on individu...
In the context of low malaria transmission, the addition of IPTp with dihydroartemisinin–piperaquine to co-trimoxazole prophylaxis in pregnant women with HIV did not reduce peripheral parasitaemia at delivery. However, the intervention was safe and ass...
In the context of low malaria transmission, the addition of IPTp with dihydroartemisinin–piperaquine to co-trimoxazole prophylaxis in pregnant women with HIV did not reduce peripheral parasitaemia at delivery. However, the intervention was safe and ass...
In The Lancet Infectious Diseases, Raquel González and colleagues1 report the results of a carefully conducted randomised placebo-controlled trial done in Gabon and Mozambique that assessed administration of monthly doses of dihydroartemisinin–piperaqu...